Growth & profitability
- Revenue has grown 622.5% per year over the past 5 years.
AVIR Financials Atea Pharmaceuticals, Inc.
8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$158M | — | — | -57.4% | -50.1% | — | — | $96M |
| 2024 | — | -$168M | — | — | -38.3% | -36.2% | — | — | $65M |
| 2023 | — | -$136M | — | — | -24.5% | -22.9% | — | — | $144M |
| 2022 | — | -$116M | — | — | -18.1% | -17.4% | -$123M | — | $188M |
| 2021 | $351M | $121M | 0.0% | 39.4% | 17.0% | 15.7% | -$87M | — | $764M |
| 2020 | $49M | -$11M | 0.0% | -22.7% | -2.0% | -1.3% | $297M | — | $850M |
| 2019 | — | -$14M | — | — | 28.3% | -63.6% | -$13M | — | $22M |
| 2018 | — | -$9M | — | — | 25.1% | — | -$8M | — | $34M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$33M | — | — | -16.1% | -14.2% | — | — | $77M |
| Mar '26 | — | -$45M | — | — | -19.4% | -17.0% | — | — | $79M |
| Dec '25 | — | -$45M | — | — | -16.3% | -14.2% | — | — | $96M |
| Sep '25 | — | -$42M | — | — | -13.3% | -12.3% | — | — | $77M |
| Jun '25 | — | -$37M | — | — | -10.2% | -9.5% | — | — | $88M |
| Mar '25 | — | -$34M | — | — | -8.3% | -7.8% | — | — | $119M |
| Dec '24 | — | -$34M | — | — | -7.6% | -7.2% | — | — | $65M |
| Sep '24 | — | -$31M | — | — | -6.8% | -6.3% | — | — | $98M |
| Jun '24 | — | -$41M | — | — | -8.5% | -7.9% | — | — | $243M |
| Mar '24 | — | -$63M | — | — | -12.5% | -11.4% | — | — | $161M |
| Dec '23 | — | -$39M | — | — | -7.1% | -6.6% | — | — | $144M |
| Sep '23 | — | -$33M | — | — | -5.7% | -5.5% | — | — | $138M |
| Jun '23 | — | -$28M | — | — | -4.7% | -4.5% | — | — | $214M |
| Mar '23 | — | -$35M | — | — | -5.7% | -5.6% | — | — | $183M |
| Dec '22 | — | -$34M | — | — | -5.4% | -5.2% | -$22M | — | $188M |
| Sep '22 | — | -$8M | — | — | -1.2% | -1.2% | -$21M | — | $176M |
| Jun '22 | — | -$31M | — | — | -4.7% | -4.5% | -$21M | — | $684M |
| Mar '22 | — | -$42M | — | — | -6.2% | -5.9% | -$59M | — | $706M |
| Dec '21 | $192M | $117M | 0.0% | 63.1% | 16.5% | 15.2% | — | — | $764M |
| Sep '21 | $33M | -$28M | 0.0% | -67.5% | -4.8% | -3.3% | — | — | $840M |
Frequently asked questions
Is AVIR growing its revenue and profit?
Over the past 5 years, Atea Pharmaceuticals, Inc.'s revenue has grown 622.5% per year. These are computed facts, not advice.
How much debt does AVIR have?
As of FY2025, Atea Pharmaceuticals, Inc. reported — of total debt against $96M of cash.
What is AVIR's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.